Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis

作者：Chakraborty, Debomita; Sumova, Barbora; Mallano, Tatjana; Chen, Chih-Wei; Distler, Alfiya; Bergmann, Christina; Ludolph, Ingo; Horch, Raymund E.; Gelse, Kolja; Ramming, Andreas; Distler, Oliver; Schett, Georg; Senolt, Ladislav; Distler, Jorg H. W.^*

来源：Nature Communications, 2017, 8(1): 1130.

DOI：10.1038/s41467-017-01236-6

• GROWTH-FACTOR-BETA
• SYSTEMIC-SCLEROSIS
• TGF-BETA
• SIGNALING ACTIVATION
• TYROSINE KINASES
• TARGETING STAT3
• CARCINOMA CELLS
• DERMAL FIBROSIS
• MOUSE MODEL
• IN-VITRO

Signal transducer and activator of transcription 3 (STAT3) is phosphorylated by various kinases, several of which have been implicated in aberrant fibroblast activation in fibrotic diseases including systemic sclerosis (SSc). Here we show that profibrotic signals converge on STAT3 and that STAT3 may be an important molecular checkpoint for tissue fibrosis. STAT3 signaling is hyperactivated in SSc in a TGF beta-dependent manner. Expression profiling and functional studies in vitro and in vivo demonstrate that STAT3 activation is mediated by the combined action of JAK, SRC, c-ABL, and JNK kinases. STAT3-deficient fibroblasts are less sensitive to the pro-fibrotic effects of TGF beta. Fibroblast-specific knockout of STAT3, or its pharmacological inhibition, ameliorate skin fibrosis in experimental mouse models. STAT3 thus integrates several profibrotic signals and might be a core mediator of fibrosis. Considering that several STAT3 inhibitors are currently tested in clinical trials, STAT3 might be a candidate for molecular targeted therapies of SSc.

• 出版日期2017-10-24